OSE Immuno: Invest Securities raises its target on the stock

(CercleFinance.com) - Invest Securities confirms its Buy rating on Ose Immuno shares, with a target price raised from 12.
4 to 13.5 euros.

The analyst points out that yesterday, the company published data at 10 weeks of treatment for its Ph IIa trial evaluating OSE-127 in ulcerative colitis.

The results were positive and statistically significant, validating the product's efficacy in the induction phase", says Invest, adding that data from the maintenance phase (6 months of treatment) are expected at the end of the year.

Following the integration of the success of this Ph IIa trial, we change the probability of reaching the market from 17% to 53%", concludes the broker.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.